Ravesan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
About Ravesan Pharmaceuticals
Ravesan Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 December 2016 (Eight years and one month 18 days old ). Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.00 M.
Santosh Bhat and Ravender Bhat serve as directors at the Company.
Company Details
-
Location
Ghaziabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24110UP2016PTC088505
-
Company No.
088505
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Dec 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Ravesan Pharmaceuticals Private Limited offer?
Ravesan Pharmaceuticals Private Limited offers a wide range of products and services, including Paracetamol Tablets, Crocin Tablets, Crocin Advance Tablet.
Who are the key members and board of directors at Ravesan Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravender Bhat
|
Director | 20-Dec-2016 | Current |
|
Santosh Bhat
|
Director | 20-Dec-2016 | Current |
Financial Performance of Ravesan Pharmaceuticals.
Ravesan Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ravesan Pharmaceuticals?
In 2017, Ravesan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹2.00 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 12 Oct 2018 | Others | ₹2.00 M | Open |
How Many Employees Work at Ravesan Pharmaceuticals?
Unlock and access historical data on people associated with Ravesan Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ravesan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ravesan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.